India to New Zealand Pharmaceutical Export

The India-New Zealand pharmaceutical trade corridor has experienced significant growth over the past decade. In 2024, India exported pharmaceutical products valued at $59.23 million to New Zealand, marking a substantial increase from previous years. This upward trajectory reflects the strengthening economic ties and the expanding demand for Indian pharmaceutical formulations in the New Zealand market.

A pivotal milestone in this bilateral trade relationship was the conclusion of the India-New Zealand Free Trade Agreement (FTA) in December 2025. The FTA is expected to eliminate tariffs on 90 pharmaceutical tariff lines, enhancing the competitiveness of Indian pharmaceutical exports. This agreement is anticipated to bolster India's market share in New Zealand's pharmaceutical imports, fostering deeper economic integration between the two nations.

India holds a significant position in New Zealand's pharmaceutical import landscape. In 2024, India was the largest supplier of pharmaceutical products to New Zealand, with exports valued at $81.43 million. This dominance underscores India's strategic importance as a key partner in meeting New Zealand's pharmaceutical needs.

The India-New Zealand FTA further solidifies this position by providing zero-duty access for Indian pharmaceutical exports. This preferential treatment is expected to enhance India's competitiveness in the New Zealand market, potentially increasing its share of New Zealand's pharmaceutical imports.

The conclusion of the India-New Zealand FTA in December 2025 marked a significant development in bilateral trade relations. The agreement is poised to eliminate tariffs on 90 pharmaceutical tariff lines, providing Indian exporters with enhanced market access and competitiveness in New Zealand.

Additionally, the repeal of the Therapeutic Products Bill in December 2024 has led to the initiation of new regulatory frameworks for medicines, medical devices, and natural health products in New Zealand. This regulatory evolution may impact the registration and approval processes for pharmaceutical products, presenting both challenges and opportunities for Indian exporters.

Indian pharmaceutical companies seeking to export to New Zealand must adhere to the regulatory requirements set by the New Zealand Medicines and Medical Devices Safety Authority (Medsafe). The registration process involves submitting a comprehensive dossier that includes product information, manufacturing details, and evidence of compliance with Good Manufacturing Practice (GMP) standards. The Common Technical Document (CTD) format is typically used for this submission.

Bioequivalence studies are often required to demonstrate that the generic product performs in the same manner as the innovator drug. The timeline for product registration can vary, but it generally takes several months, depending on the complexity of the product and the completeness of the submitted documentation.

New Zealand mandates that pharmaceutical products imported into the country be manufactured in facilities that comply with WHO-GMP standards. Indian manufacturers must ensure that their production sites meet these international standards to gain approval for export. The inspection process involves a thorough evaluation of the manufacturing facility's compliance with GMP guidelines.

The India-New Zealand FTA includes provisions for mutual recognition of major regulatory inspections, which is expected to streamline the approval process for Indian pharmaceutical products in New Zealand. This alignment aims to reduce compliance barriers and expedite market entry for Indian exporters.

To import pharmaceutical products into New Zealand, Indian exporters must provide several key documents, including:

• Certificate of Pharmaceutical Product (CPP): Certifies that the product is authorized for sale in the country of origin.

• Certificate of Analysis (CoA): Provides detailed information on the product's composition and quality.

• GMP Certificate: Confirms that the manufacturing facility adheres to GMP standards.

These documents are essential for customs clearance and regulatory approval. The import process also involves compliance with New Zealand's customs procedures, which include the payment of applicable duties and taxes, as well as adherence to any specific import restrictions or requirements.

The majority of India's pharmaceutical exports to New Zealand consist of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. In 2024, these products accounted for a significant portion of the export value. This trend aligns with New Zealand's healthcare needs, which are increasingly met by ready-to-use pharmaceutical products.

The therapeutic areas dominating these exports include cardiovascular drugs, central nervous system agents, and anti-infectives. This focus reflects the prevalent health concerns in New Zealand, such as heart disease, diabetes, and infectious diseases.

The India-New Zealand FTA is expected to open new avenues for Indian pharmaceutical exporters, particularly in the biologics and biosimilars sectors. With the global patent expiry of several blockbuster biologic drugs, there is a growing demand for biosimilars, presenting an opportunity for Indian companies to expand their product offerings in New Zealand.

Additionally, the evolving regulatory landscape in New Zealand may create opportunities for Indian exporters to introduce innovative formulations and new therapeutic areas, provided they can navigate the updated approval processes effectively.

New Zealand's aging population and the increasing prevalence of chronic diseases are significant drivers of pharmaceutical import demand. The country's healthcare system relies on a diverse range of imported pharmaceutical products to meet the needs of its population. The India-New Zealand FTA is expected to further stimulate demand for Indian pharmaceutical products by enhancing their competitiveness and availability in the New Zealand market.

Under the India-New Zealand FTA, New Zealand has committed to providing 100% duty-free market access across all tariff lines for India's current exports, including pharmaceuticals. This eliminates previous peak tariffs of up to 10% on key products, enhancing the price competitiveness of Indian pharmaceutical exports in New Zealand.

The FTA also outlines a phased elimination of tariffs on certain products, balancing liberalization with the protection of sensitive sectors. This structured approach aims to provide Indian exporters with improved market access while considering New Zealand's domestic economic priorities.

The India-New Zealand FTA, concluded in December 2025, is a landmark agreement that is expected to significantly boost bilateral trade, including in the pharmaceutical sector. The agreement includes provisions for mutual recognition of major regulatory inspections, which is anticipated to streamline the approval process for Indian pharmaceutical products in New Zealand.

Additionally, the Comprehensive and Progressive Agreement for Trans-Pacific Partnership (CPTPP), of which New Zealand is a member, includes provisions related to pharmaceuticals. However, these provisions do not change New Zealand's Pharmaceutical Management Agency (PHARMAC) model or its ability to negotiate the best price for medicines for New Zealanders. (mfat.govt.nz)

The India-New Zealand FTA includes commitments on intellectual property, including provisions related to patents and data protection. However, the agreement does not contain obligations on data protection or market protection for new pharmaceutical products, including biologics. This means that Indian generic manufacturers may face fewer barriers to entry in the New Zealand market, potentially enhancing their competitiveness. (mfat.govt.nz)

Pharmaceutical shipments from India to New Zealand primarily utilize sea freight, with major ports such as Nhava Sheva (Jawaharlal Nehru Port) serving as key export points. The transit time for sea shipments from India to New Zealand typically ranges from 20 to 30 days, depending on the specific ports and shipping routes.

Air freight is also utilized for time-sensitive deliveries, with transit times of approximately 10 to 15 days. However, air freight costs are significantly higher than sea freight, which can impact the overall cost-effectiveness of shipments.

In India, major export ports for pharmaceutical products include Nhava Sheva (Jawaharlal Nehru Port), which handles a significant portion of the country's pharmaceutical exports. In New Zealand, Auckland is the primary import port for pharmaceutical products, accounting for a substantial share of the country's pharmaceutical imports.

The efficiency and capacity of these ports are crucial for ensuring timely and secure delivery of pharmaceutical shipments. Ongoing investments in port infrastructure and logistics are expected to further enhance the efficiency of the India-New Zealand pharmaceutical trade corridor.

Maintaining the integrity of pharmaceutical products during transit is paramount. Both India